Sotera Health Business Summary

Sotera Health Co (SHC) operates a mission-critical service model providing end-to-end sterilization, lab testing, and advisory services for the global healthcare industry. The company generates revenue primarily through high-tenure, multi-year service contracts—accounting for over 70% of total sales—across three core business segments: Sterigenics (outsourced terminal sterilization using gamma, ethylene oxide, and E-beam technologies), Nordion (a product-based segment supplying Cobalt-60 and gamma technologies), and Nelson Labs (microbiological testing and validation). As of February 2026, the company maintains a dominant market position, serving 40 of the top 50 medical device firms and 9 of the top 10 pharmaceutical companies, with 2025 revenues projected to exceed $1.16 billion. Its primary direct competitors include STERIS AST, Charles River Laboratories, and Eurofins Scientific, against whom Sotera differentiates through its vertically integrated supply of radioisotopes and an extensive global network of over 60 facilities. The company was formally established in 2017 through a strategic consolidation of legacy entities Sterigenics, Nordion, and Nelson Labs, orchestrated by private equity firms Warburg Pincus and GTCR. The current leadership team is headed by Chairman and CEO Michael B. Petras, Jr., a former GE executive with extensive industrial leadership experience, and SVP/CFO Jonathan M. Lyons. Key operational leadership includes Michael P. Rutz (President, Sterigenics), Riaz Bandali (President, Nordion), and Joseph A. Shrawder (President, Nelson Labs). The board of directors was recently expanded in February 2026 with the appointment of Richard G. Kyle, former CEO of The Timken Company, as an independent director. Despite recent secondary offerings, Warburg Pincus and GTCR remain influential stakeholders, with James C. Neary of Warburg Pincus continuing to serve on the board alongside Lead Independent Director Vincent K. Petrella.